Nurix Therapeutics, Inc. Profile Avatar - Palmy Investing

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's t…

Biotechnology
US, San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Nurix Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of NRIX's Analysis
CIK: 1549595 CUSIP: 67080M103 ISIN: US67080M1036 LEI: - UEI: -
Secondary Listings
NRIX has no secondary listings inside our databases.